Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq by Limonciel, A. et al.
Vol.:(0123456789) 
Archives of Toxicology (2018) 92:2517–2531 
https://doi.org/10.1007/s00204-018-2256-2
TOXICOGENOMICS
Comparison of base-line and chemical-induced transcriptomic 
responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq
Alice Limonciel1,3 · Gamze Ates2 · Giada Carta1,3 · Anja Wilmes1,3 · Manfred Watzele4 · Peter J. Shepard5 · 
Harper C. VanSteenhouse5 · Bruce Seligmann5 · Joanne M. Yeakley5 · Bob van de Water6 · Mathieu Vinken2 · 
Paul Jennings1,3 
Received: 18 August 2017 / Accepted: 4 July 2018 / Published online: 14 July 2018 
© The Author(s) 2018
Abstract
The utilisation of genome-wide transcriptomics has played a pivotal role in advancing the field of toxicology, allowing the 
mapping of transcriptional signatures to chemical exposures. These activities have uncovered several transcriptionally regu-
lated pathways that can be utilised for assessing the perturbation impact of a chemical and also the identification of toxic mode 
of action. However, current transcriptomic platforms are not very amenable to high-throughput workflows due to, high cost, 
complexities in sample preparation and relatively complex bioinformatic analysis. Thus, transcriptomic investigations are 
usually limited in dose and time dimensions and are, therefore, not optimal for implementation in risk assessment workflows. 
In this study, we investigated a new cost-effective, transcriptomic assay, TempO-Seq, which alleviates the aforementioned 
limitations. This technique was evaluated in a 6-compound screen, utilising differentiated kidney (RPTEC/TERT1) and liver 
(HepaRG) cells and compared to non-transcriptomic label-free sensitive endpoints of chemical-induced disturbances, namely 
phase contrast morphology, xCELLigence and glycolysis. Non-proliferating cell monolayers were exposed to six sub-lethal 
concentrations of each compound for 24 h. The results show that utilising a 2839 gene panel, it is possible to discriminate 
basal tissue-specific signatures, generate dose–response relationships and to discriminate compound-specific and cell type-
specific responses. This study also reiterates previous findings that chemical-induced transcriptomic alterations occur prior 
to cytotoxicity and that transcriptomics provides in depth mechanistic information of the effects of chemicals on cellular 
transcriptional responses. TempO-Seq is a robust transcriptomic platform that is well suited for in vitro toxicity experiments.
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Introduction
A distinct advantage of in  vitro techniques over whole 
animal models is their applicability to mechanistic inves-
tigations and the ability to use cells of human origin. 
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Mechanistic-based assays are rapidly becoming the corner-
stone of contemporary toxicological investigations, driven 
by advances in genetic analysis and associated omic meth-
odologies. Transcriptomics has been a key tool in allow-
ing a better understanding of how the cellular program is 
altered in response to stress situations (Jennings et al. 2013). 
However, whole genome arrays are still too expensive to 
be considered for routine use. Additionally, RNA sample 
preparation and post-analysis is cumbersome when sample 
numbers are large. Thus, multiple compound concentrations 
and/or temporal effects are seldom studied in transcriptomic 
investigations and toxicogenomic data is often limited in 
dimension (Wilmes et al. 2011, 2013). Where complete dose 
responses were conducted, for example, by Waldmann et al., 
the chemical-induced alterations in transcriptomic expres-
sion were shown to manifest at concentrations well below 
alterations in cell viability (Waldmann et al. 2014). Thus, if 
transcriptomic assays become cheaper and easier to perform, 
it is likely to become a dominant methodology for hazard 
and risk assessment, due to the wealth of mechanistic infor-
mation it provides.
In the present study we investigated the utility of a 
new, cost-effective technique templated oligo assay with 
sequencing readout (TempO-Seq) that solves both the cost 
and throughput issues (Grimm et al. 2016; Yeakley et al. 
2017). TempO-Seq is an NGS library preparation method 
that is based on ligation of detector oligos that are hybrid-
ized directly to RNA targets, with the subsequent addition of 
sample barcodes and sequencing adapters by PCR amplifica-
tion. In addition, there is no RNA extraction step required. 
The detector oligos are chimeric and contain a sequence spe-
cific to the targeted RNA as well as a sequence in common 
among the detector oligos for universal primers. TempO-
Seq thus allows cost-effective, simultaneous quantification 
of specific mRNA targets without the need to isolate RNA. 
In this particular study, we utilised a probe set identifying 
2839 genes which is a combination of a previously selected 
gene panel (Mav et al. 2018) supplemented with knowledge-
based cellular stress response-related genes identified by the 
experiences of the academic groups in this publication. The 
entire gene set utilised is provided in Table S1. The Mav 
et al. gene-set was developed by the U.S. Tox21 Federal 
collaboration program and represents a data-driven strategy 
of sentinel genes (selected for biological diversity, maximal 
information content, and widespread pathway coverage), 
which was also augmented using a knowledge-driven selec-
tion of additional genes (Mav et al. 2018).
Two of the major target organs for systemic toxicology 
are the liver and kidney. While renal and hepatic in vitro 
systems are often run within the same project umbrella, they 
are not usually challenged with the same compounds at the 
same concentrations. This makes it difficult to compare 
data and draw conclusions pertaining to tissue-specificity 
of responses and tissue-specific biomarkers. Here we uti-
lised a human renal and human hepatic cell line (RPTEC/
TERT1 and HepaRG, respectively). RPTEC/TERT1 and 
HepaRG are considered the most differentiated and stable 
cell lines currently available for their respective tissues and 
thus the most applicable for in vitro toxicological investiga-
tions (Guillouzo et al. 2007; Doktorova et al. 2013; Aschauer 
et al. 2013, 2015). Both cell types were used for drug expo-
sures under serum-free conditions and under differentiated 
non-proliferating monolayer conditions. The cells were 
exposed to the same six compounds at the same concentra-
tions, measuring the same endpoints (impedance, glycolysis, 
morphology, and targeted TempO-Seq transcriptomics). The 
six structurally unrelated compounds selected were ochra-
toxin A (OTA), potassium bromate  (KBrO3), cyclosporine A 
(CsA), acetaminophen (APAP), isoniazid (ISZ) and sodium 
valproate (VALP). While some of these may be considered 
preferentially nephrotoxic or hepatotoxic, in reality, many 
adversely affect both organs and in addition pharmacoki-
netic properties are likely to play a major role in target organ 
specificity in vivo.
The present study demonstrates the usefulness of the 
TempO-Seq methodology, identifies differences in RPTEC/
TERT1 and HepaRG expressed transcriptomes, differences 
in toxicological responses and identifies chemical- and tis-
sue-specificity of certain gene and pathway responses.
Materials and methods
Routine cell culture and differentiation
The hepatic cell line, HepaRG (Guillouzo et al. 2007), was 
obtained from BioPredic International and the renal proxi-
mal tubule cell line, RPTEC/TERT1 (Wieser et al. 2008), 
from Evercyte GmbH. HepaRG cells were routinely cultured 
in William’s E medium (Gibco 12551032) supplemented 
with 2 mM Glutamax, 5 µg/ml insulin, 50 µM hydrocor-
tisone 21-hemisuccinate, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 9% Foetal Calf Serum (FCS) (all compo-
nents were from BioPredic International). RPTEC/TERT1 
cells were routinely cultured, differentiated and exposed 
to chemicals in a 1:1 mix of DMEM (Gibco 11966-025) 
and Ham’s F12 (Gibco 21765-029) (containing a final con-
centration of 5 mM glucose) and supplemented with 2 mM 
Glutamax, 10 ng/ml epidermal growth factor, 36 ng/ml 
hydrocortisone, 5 µg/ml insulin, 5 µg/ml transferrin, 5 ng/ml 
selenium, 100 U/ml penicillin and 100 µg/ml streptomycin 
(Jennings et al. 2009). Cells were cultured in a controlled 
humidified 37 °C, 5%  CO2 environment. Cells were rou-
tinely passaged once a week in trypsin EDTA. HepaRG cells 
were differentiated according to Biopredic’s 6 day protocol 
(Biopredic International 2017). Briefly, cells were seeded on 
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10 µg/cm2 collagen I (Biopredic) coated 12 well or 96 well 
plates in base William’s E medium with GlutaMAX and 
ADD670 additives (Biopredic). Medium was changed after 
24 h to maintenance/metabolism medium (base medium 
with ADD620 additives) and renewed after 48 h. Three 
days later the medium was changed to Induction medium 
(base medium with ADD650 serum-free additives). RPTEC/
TERT1 cells were differentiated by allowing them to reach 
confluence and remain in a confluent state for at least 7 days 
before treatment as previously described (Aschauer et al. 
2013).
Chemical exposures
From the past experiences of the two experienced testing 
laboratories (i.e., Medical University of Innsbruck, MUI, 
and the Vrije Universiteit Brussel, VUB), a panel of six 
unrelated compounds and associated concentrations were 
selected (Table 1). Differentiated cell monolayers were 
washed and treated with the compounds in serum-free 
medium for 24 h. All compounds, except for CsA, were 
water soluble. Stock solutions of CsA (15 mM) were made 
in 100% DMSO, aliquoted and frozen. All final concentra-
tions for CsA had a 0.1% DMSO content and 0.1% DMSO 
was used as a vehicle control. OTA was made up to 2.48 mM 
in supplemented DMEM/Ham’s F12 aliquoted and frozen. 
All other stocks were generated in either HepaRG complete 
medium or RPTEC/TERT1 complete medium and used 
freshly (Table 1).
xCELLigence assay
xCELLigence experiments were conducted at the MUI 
laboratory. Cells were seeded in the proprietary E-Plates 
containing the impedance gold electrodes in 60 µl medium 
and differentiated. Impedance was measured intermittently 
using the RTCA unit in a cell culture incubator. At time of 
exposure impedance was measured every 5 min for the 24-h 
duration. Cell index (CI) was normalised to the impedance 
before measurement per well.
TempO‑Seq assay
Three separate batches of HepaRG and RPTEC/TERT1 
were cultured in separate medium stocks and seeded and 
differentiated in 12-well plates. The HepaRG and RPTEC/
TERT1 experiments were conducted at the VUB and the 
MUI, respectively. The three biological replicates of differ-
entiated cells were exposed to chemicals, medium controls 
and 0.1% DMSO controls for 24 h in serum-free medium. 
Morphology was documented by phase contrast micros-
copy (Fig. 2). Wells were washed in 1 ml PBS (DPBS, 
Gibco, 14190-094) and lysed in 750 µl of 1× BioSpyder 
lysis buffer. Lysates were frozen at − 80 °C and shipped to 
BioSpyder technologies on dry ice where the TempO-Seq 
assay was conducted.
Cellular extracts were harvested for TempO-Seq analy-
sis to quantify the 3050 probe set representing 2839 genes 
(Table S1). A pair of detector oligos were annealed to adja-
cent 25 nt sequences in the target RNA, after which excess 
oligos were digested with a nuclease, and remaining oligos 
were ligated (Yeakley et al. 2017). This process occurred 
as a homogenous assay through progressive dilution to 
ensure enzyme compatibility and was, therefore, free of 
Table 1  Concentrations of chemicals used with vehicle and ordering information
0–5 are the dilutions, all values are expressed in µM unless otherwise stated
Tested concentrations in µM
Name Ochratoxin A Potassium Bromate Cyclosporine A Na valproate Acetaminophen Isoniazid
Short name OTA KBrO3 CsA VALP APAP ISZ
Dilution
 0 0 0 0 0 0 0
 1 0.001 80 0.05 8 8 8
 2 0.01 400 1 40 40 40
 3 0.13 800 5 200 200 200
 4 1 2000 10 1000 1000 1000
 5 10 4000 15 5000 5000 10,000
Pre-stock 2.48 mM – 15 mM – – –
Vehicle RPTEC/TERT1 Medium RPTEC/TERT1 Medium DMSO HepaRG medium HepaRG medium HepaRG medium
Source Sigma Sigma Calbiochem Sigma Sigma Sigma
Cat No O1877 P7332 239835 P4543 A7302 I3377
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the need for bead-based clean-up or poly (A) + selection. 
Furthermore, the assay did not require RNA purification 
or cDNA synthesis. Once ligated, the detector oligos acted 
as templates in a PCR-based amplification to add sequenc-
ing adapters for an Illumina instrument and sample bar-
codes. Since all the detector oligos share the same pair 
of primer landing sites, the assay could be multiplexed 
with respect to the RNA targets, but still single plex with 
respect to the primers. The PCR primers both include a 
9-mer index sequence, different for the primers used to 
amplify each sample, that resulted in dual index sample 
barcodes, allowing pooling post-PCR of up to 384 samples 
in 1 library. The number of samples per library depends 
on the sequencing depth achievable for a given instrument 
and the read depth desired. For a detector pool of ~ 3 K 
targets, between 0.5M and 3M reads per sample should 
give correlations of  R2 = ~ 0.97 for technical replicates of 
100 ng purified total RNA. Each sample fastq file was 
aligned against the TempO-Seq transcriptome using the 
Bowtie aligner (Li and Durbin 2009). The output of this 
analysis generated a table of counts per gene per sample.
Lactate assay
Supernatant samples from the same TempO-Seq run were 
centrifuged at 150 g for 5 min to remove free floating 
cells. The supernatant was frozen at − 20 °C until assay. 
Samples from the VUB lab were transferred to the MUI 
lab for assay. In a 96 well microtitre plate 10 µl super-
natant medium was incubated with 90 µl lactate reagent 
buffer (86 mM Triethanolamine HCl, 8.6 mM EDTA.Na2, 
33 mM  MgCl2, 326 µM N-methylphenazonium methyl 
sulphate (PMS), 790 µM p-iodonitrotetrazolium violet 
(INT), 3.37 mM β-NAD, 7% ethanol, 0.4% Triton-X-100, 
4 U/ml Lactate Dehydrogenase) for approximately 7 min 
at room temperature, as previously described (Limonciel 
et al. 2011). Optical density was measured in a Tecan 
Infinite M200 at 490 nm. An 8-point calibration curve 
starting with 25 mM lactate was used to determine actual 
concentrations. To avoid confusion we wish to clarify that 
this assay measures the metabolite lactate, not the activity 
of the lactate dehydrogenase enzyme, which is often used 
as a cell viability (plasma membrane integrity) assay.
Data analysis and visualisation
TempO-Seq sample outliers were assessed for the two cell 
types independently and identified using both the Tukey’s 
and Grubb’s outlier tests. No outliers were uncovered in 
this sample set. Normalization and differential expression 
were performed using the DESeq2 package (Love et al. 
2014). To perform differential expression analysis, each 
treatment condition was paired with the appropriate con-
trol and the counts for each sample were then normalized 
using the DESeq2 estimateSizeFactors function. Differen-
tial expression of each treatment relative to its respective 
control was measured using the Wald test. Probes with 
Benjamin Hochberg adjusted p values ≤ 0.05 were con-
sidered significantly differentially expressed.
Heat maps were generated using the conditional for-
matting function of Microsoft Excel (version 1803). 
Genes were assigned to ATF4, Nrf2 or p53 pathways 
using information from several published sources (Riley 
et al. 2008; Limonciel et al. 2015). For a complete list of 
pathway allocations and sources see Table S3. Toxico-
logical Prioritization Index (ToxPi) visualisations were 
generated using the National Center for Computational 
Toxicology, U.S. EPA’s ToxPi software version 2.0 (Reif 
et al. 2013; Marvel et al. 2018). The linear algorithm 
was used for all Pis, with equal weightings. The complete 
input file for the ToxPi software is given in Table S5.
Statistical analysis
For concentration dependent analysis a one-way ANOVA 
with Dunnett’s post-test vs control (lactate and individual 
genes) was conducted. For time and concentration analysis a 
two-way ANOVA was used with a Sidak’s post-test (xCEL-
Ligence). Both were generated using GraphPad Prism ver-
sion 6. See legends for specific details.
Results
The control samples, consisting of three medium con-
trols and three 0.1% DMSO treated controls per cell line, 
were used to compare the baseline gene expression of dif-
ferentiated HepaRG and RPTEC/TERT1 cells (Fig. 1 and 
Table S2). While RPTEC/TERT1 and HepaRG exhibited 
a similar expression of the majority of genes (Fig. 1a inset, 
Table S2A), 519 genes had significantly different basal 
expression levels in the two cell lines (Fig. 1 main, Fig. 1b 
and Table S2B). HepaRG exhibited significantly higher 
expression of genes encoding plasma proteins, including 
albumin (ALB), haptoglobin (HP), transthyretin (TTR), 
alpha fetoprotein (AFP), alpha-2-macroglobulin (A2M), 
apolipoproteins (APOA1, APOC1, APOE), fibrinogen 
(FGG, FGB) and complement proteins (C3, C1R and 
CFH), genes involved in xenobiotic metabolism, includ-
ing cytochrome P450s (CYP3A4, CYP3A5, CYP2E1), 
N-acetyltransferase 2 (NAT2), carboxylesterase 1 (CES1), 
and other known liver-specific genes, including fatty acid 
binding protein 1 (FABP1), orosomucoid 1 and 2 (ORM1, 
ORM2), ABCC2, alcohol dehydrogenase (ADH1A and 
1B), SLCO1B1, SLCO2B1, bile acid-CoA:amino acid 
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N-acyltransferase (BAAT), genes involved in the urea cycle 
Arginase 1 (ARG1) and the transcription factor hepatocyte 
nuclear factor 4 alpha (HNF4A). HepaRG, compared to 
RPTEC/TERT1 cells also highly express Epiregulin (EREG) 
and several genes associated with cancer, many belonging 
to the GAGE family (GAGE − 1, − 2, − 3, − 4 and − 12).
RPTEC/TERT1 cells exhibited a higher expression 
of genes including the nephrogenic transcription fac-
tor PAX8, the tight junction protein claudin 2 (CLDN2), 
SLC7A5 and SLC3A2 (the genes encoding the proteins for 
the large neutral amino acid transporter LAT1), the brush 
border enzyme gamma glutamyl transferase (GGT1), col-
lagen 4A (COL4A), methionine adenosyltransferase 2A 
(MAT2A), secreted phosphoprotein 1 (SPP1), mal, T-cell 
differentiation protein 2 (MAL2), ATP binding cassette sub-
family C members (ABCC 4 and 5), phosphofructokinase 
(PFKP), gamma-butyrobetaine hydroxylase 1 (BBOX1), 
vimentin (VIM), ATPase Na+/K+ transporting subunit beta 
1 (ATP1B1), the proton pump (ATP6VOE1), glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), ribosomal protein 
S7 (RPS7), amyloid beta precursor protein (APP), myosin 
X (MYO10), NAD(P)H quinone dehydrogenase 1 (NQO1), 
mucin 1 (MUC1), adhesion molecule with Ig like domain 2 
(AMIGO2) and plasminogen activator urokinase (PLAU).
Upon exposure to the selected compounds, temporal 
alterations in impedance utilising the xCELLigence system 
showed an initial spike after all treatments in both cell lines, 
presumably due to the manipulation of the cells outside the 
Fig. 1  Comparison of HepaRG 
and RPTEC/TERT1 transcrip-
tome. From a total of 3050 
probes (inset a), probes were 
filtered for significant difference 
between the in vitro models (p 
value < 0.001) and with a coef-
ficient of variance greater than 
0.6. a Plot of HepaRG mRNA 
values against the correspond-
ing RPTEC/TERT1 values. b 
Most abundant 15 genes from 
the 105 genes which are exclu-
sively expressed in 1 model. All 
values are given in Table S2A 
and S2B
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incubator (Fig. 2a, b). The xCELLigence apparatus measures 
net impedance of each well, reported as Cell Index (CI), 
with high temporal resolution (Kustermann et al. 2013; Kho 
et al. 2015). CI is dependent on the amount of cells attached 
to the well, the forces at which they bind and the net vol-
ume of the cells per well and is considered a sensitive label-
free viability assay (Ke et al. 2011). RPTEC/TERT1 cells 
exhibited an oscillating CI, compared to the smooth CI of 
HepaRG cells. RPTEC/TERT1 monolayers due to vectorial 
solute and water transport, form raised areas called, domes 
(Wieser et al. 2008; Aschauer et al. 2013). Where a dome 
forms, the cells are no longer in contact with the electrode 
and thus do not contribute to impedance. Since, domes are 
dynamic and are formed and collapse overtime, the CI pat-
tern appears ruffled. The strongest compound effect observed 
in RPTEC/TERT1 was with 4000 µM  KBrO3. This condi-
tion resulted in an increase of CI, beginning at 9-h exposure 
(Fig. 2a), which is likely due to toxicity induced decrease in 
dome formation. In HepaRG 4000 µM  KBrO3 also showed 
the strongest effect, with a decrease in CI starting at 15-h 
exposure (Fig. 2b). Enhanced glycolysis, as measured by 
supernatant lactate, was observed in RPTEC/TERT1 cells 
only, and only in two conditions: CsA 15 µM and  KBrO3 
4000 µM (Fig. 2c). VALP caused a slight decrease in lactate 
production at the highest concentration in RPTEC/TERT1 
cells (Fig. 2c). Phase contrast morphology shows a typical 
representation of differentiated RPTEC/TER1 cells and dif-
ferentiated HepaRG cells; with a complete monolayer, cob-
ble stone morphology and dome formation in the RPTEC/
TERT1 controls (Fig. 2d) and a mixture of compact hepat-
ocyte-like cells and biliary epithelial-like cells for HepaRG 
cells (Fig. 2e). Morphological aberrations were observed 
only with  KBrO3 at 4000 µM in RPTEC/TERT1 cells, with 
small holes visible in the monolayer (Fig. 2d, e).
Figure 3 shows the read counts, differentially expressed 
probes (DEP) and a heat map of genes which were differen-
tially expressed compared to controls in at least 2 of the 60 
conditions (i.e., cell type, compounds, and concentration). 
The treatments had no discernible effect on read counts 
(Fig. 3a). There was, however, a concentration-dependent 
increase (i.e., an increase in at least two consecutive concen-
trations) in the number of DEPs for all compounds except 
ISZ. OTA had the strongest impact on DEPs, followed by 
 KBrO3, CsA, VALP, APAP, and ISZ. (This does not reflect 
the potency ranking as different concentrations were used.) 
Based on the first concentration with an increase in DEP, 
A RPTEC/TERT1: impedance
B HepaRG: impedance
OTA 10 µM Mµ0005PAPAlortnoc




OTA 10 µM Mµ0005PAPAlortnoc







Fig. 2  xCELLigence, lactate production and morphology after 24  h 
single application exposures. a, b Impedance measurements utilis-
ing the xCELLigence system with the same concentrations as utilised 
for the transcriptomics study. The values are mean from three bio-
logical replicates. *Indicates a significant difference using a two-way 
ANOVA, using a Sidak’s post-test with a significant cut off of 0.05. c 
Supernatant lactate from the same cultures utilised in the transcrip-
tomic study. Values are mean fold control (FC) ± standard deviation. 
*Indicates a significant difference using a one-way ANOVA, using 
a Dunnett’s post-test with a significant cut off of 0.05. d, e Phase 
contrast morphology of cells with the highest concentration of com-
pounds
2523Archives of Toxicology (2018) 92:2517–2531 
1 3
RPTEC/TERT1 were more sensitive to OTA and  KBrO3, 
and sensitivities for the rest of the compounds were similar.
The data are also visualised using ToxPi with the slices 
representing DEP, genes in the ATF4 (major branch of the 
unfolded protein response), Nrf2 and p53 pathway (Fig. 4). 
It should be noted that the ToxPi charts do not show direc-
tionality of the genes in the pathway, just overall impact. 
Utilising the hierarchical clustering feature, three main clus-
ters were apparent (Fig. 4). The yellow cluster represents 
the concentrations that had the highest impact on the four 
parameters and includes the two highest concentrations of 
OTA and  KBrO3 for both cell types (OTA_H4,H5, OTA_
R4,R5,  KBrO3_H4,H5,  KBrO3_R4,R5) and the highest con-
centration of CsA in RPTEC/TERT1 cells (CsA_R5). The 
Fig. 3  Effect of compounds 
on read counts (a), differential 
gene expression per treatment 
(b) and individual differential 
gene expression (c). The total 
read counts (×1000) are plotted 
versus concentration per cell 
model. b The number of total 
differentially expressed genes 
(with a significance cut off 
Benjamini Hochberg adjusted 
p > 0.05), are plotted versus 
concentration per cell model. 
The numeric values are given in 
the tables. c Heat map of log2 
fold control data from 1514 
genes that were significantly 
altered in 2 or more condi-
tions. The heat map is sorted 
by the sum across all condi-
tions per gene. R is RPTEC/
TERT1, H is HepaRG. The red 
colour indicates increased and 
blue decreased, where white is 
unchanged. Where the log2 fold 
control could not be calculated 
(i.e., a division by zero error 
where all values zero in the 
control) the value is also repre-
sented by a white. The values at 
the bottom of the heat map are 
the sum of the DEGs over the 
5 concentrations per cell line 
(maximum possible is 7570). 
The values behind the heat map 
with the gene annotations are 
given in Table S4
KBrO3
R H R H R H R H R H R H
VALPCsA APAP ZSIATO
2052 1119 1155 1551 633 444 551 278 322 211 23       39
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green cluster represents the conditions that had a medium 
impact and the purple cluster contains mild to zero impact. 
All of the ISZ compounds were in the green cluster. In the 
lower panels of Fig. 4 the ToxPis are organised per com-
pound and cell type. OTA had a strong impact on all three 
pathways, but the impact was larger in RPTEC/TERT1 cells. 
 KBrO3 had a strong impact the Nrf2 and p53 pathways. Both 
CsA and APAP had a stronger impact on the ATF4 path-
way and this was larger in RPTEC/TERT1 cells. In RPTEC/
TERT1 cells VALP had a prominent effect only on the Nrf2 
pathway. None of the selected pathways were impacted on 
by ISZ in either cell type.
Quantitative data for 27 selected representative genes 
is given graphical form as non-transformed and in heat 
maps as log2 fold control transformed data (Fig. 5). The 
first panel of nine represent genes in the Nrf2 (HMOX1, 
SRXN1 and GCLM), p53 (GADD45A, CDKN1A, SFN) 
and ATF4 pathways (ASNS, TRIB3, DDIT3) (Fig. 5a). For 
the Nrf2 genes, HMOX1 was more responsive in RPTEC/
TERT1 cells, while SRXN1 and GCLM showed similar 
levels of induction (Fig. 5a).  KBrO3 was the strongest 
inducer of these genes. At the highest concentration of 
OTA HMOX1 was significantly decreased in RPTEC/
TERT1 and GCLM significantly decreased in both cell 
types. For the p53 genes, GADD45A, CDKN1A and SFN 
showed similar levels of induction in both cell types and 
again  KBrO3 was the highest inducer. OTA decreased 
SFN at the highest 2 concentrations in HepaRG cells. 
For the ATF4 genes, both TRIB3 and DDIT3 were more 
responsive in RPTEC/TERT1, whereas ASNS showed a 
similar level of maximum induction in both cell types. 
CsA, particularity in RPTEC/TERT1 cells, was the highest 
inducer of these three genes, but the highest concentration 
of APAP also resulted in a significant increase in ATF4 
genes in both cell types. OTA decreased TRIB3 in both 
cell types.
Fig. 4  Representation of 
compound-induced differen-
tially expressed genes using 
ToxPi visualisations. The 
ToxPi v 2 software was used to 
generate the diagrams. The top 
panel shows a full pie with its 
colour codes and gene numbers 
each slice uses the linear model. 
DEP is differentially expressed 
probes. The numbers for p53, 
Nrf2 and ATF4 represent the 
no. of genes allocated to those 
pathways (see Table S3). On 
the right of the top panel is a 
Hierarchical Clustering using 
ward.D2. Labelling of samples 
is compound code, the dilution 
(as per Table 1), R for RPTEC/
TERT1 and H for HepaRG The 
lower panels show the ToxPis 
per cell type, compound and 
concentrations, where numbers 
represent the µM concentration 
of the corresponding compound. 
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Examples of HepaRG responsive genes are given in 
Fig. 5b. CYP3A4, EREG, A2M, ARG1, HNF4A, ADH1A 
were unresponsive in RPTEC/TERT1 cells. AFP, BAAT and 
HPR showed some mild induction in certain exposures in 
RPTEC/TERT1. All of these 9 genes were robustly respon-
sive with at least one of the compounds in HepaRG. APAP 
was a strong inducer of CYP3A4; OTA and  KBrO3 were 
inducers of AFP; while  KBrO3 and VALP were inducers of 
HMOX1, heme oxygenase 1
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Fig. 5  Concentration response relationships of selected genes, repre-
senting a stress response pathways, b HepaRG-specific and c RPTEC/
TERT1-specific. In the graphs the values are expressed as mean 
mRNA expression ± SEM. In the heat map values represent the mean 
log2 fold control with red representing the highest value and blue the 
lowest. White represents either 0 or absent. Statistical significance to 
control (p < 0.05) is denoted by * for RPTEC/TERT1 and # for Hep-
aRG using a one-way ANOVA, with a Dunnett’s post-test and signifi-
cant cut off of 0.05
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EREG. A2M, ARG1, BAAT, HNF4A, ADH1A and HPR 
were mostly decreased in the chemical exposures, which was 
particularly predominant with  KBrO3 exposure.
Examples of RPTEC/TERT1 responsive genes are given 
in Fig. 5c. SPP1, SLC7A5, ME1, BBOX1, and MUC1 were 
unresponsive in HepaRG cells. APP, CLDN2, ATP1B1 and 
AMIGO2 showed some mild responses in HepaRG. All of 
these 9 genes were robustly responsive with at least three of 
the compounds in RPTEC/TERT1. SPP1 was induced by 
OTA,  KBrO3 and CsA. APP was induced by all compounds 
CYP3A4, cytochrome P450 family 3 subfamily A member 4
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Fig. 5  (continued)
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except CsA. SLC7A5, which is also an ATF4 responsive 
gene, was induced by CsA, APAP and VALP. ME1, which 
is an Nrf2 responsive gene was induced by  KBrO3, CsA 
and VALP. BBOX1, CLDN2, ATP1B1 and MUC1 were fre-
quently decreased in chemical exposures, however, all were 
induced by ISZ. AMIGO2 was induced by CsA and VALP 
(VALP was biphasic), whereas OTA and APAP attenuated 
AMIGO2.
SPP1, secreted phosphoprotein 1
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Fig. 5  (continued)
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Discussion
The main aim of this study was to investigate the use of 
the TempO-Seq platform for application to in vitro toxicol-
ogy. Comparison of the base-line expression of the 2 cell 
types uncovered a clear separation of 519 genes (Fig. 1 and 
Table S2B). HepaRG cells differentially expressed genes 
related to their liver origin including; plasma proteins, 
metabolising enzymes, and mediators of fatty acid metabo-
lism. There was also high expression of GAGE isoforms and 
EREG, which likely relates to their cancer origin as com-
pared to the non-cancerous RPTEC/TERT1 cells (Wieser 
et al. 2008). The RPTEC/TERT1 cell line, differentially 
expressed genes involved in renal phenotype including; 
transport, tight junction formation, and energy metabolism. 
Thus, the targeted gene panel, and the cell types utilised, 
captured renal and hepatic phenotypes. Challenging the cells 
with six compounds at six concentrations revealed a clear 
concentration–response relationship in the total number of 
differentially expressed probes for all compounds except 
ISZ. (Here concentration–response is defined as an increase 
in at least two consecutive concentrations and ISZ had an 
effect only at the highest concentration). Taking into con-
sideration the concentrations applied, the potency ranking 
was OTA > CsA > KBrO3 > VALP > APAP > ISZ. RPTEC/
TERT1 cells were more sensitive to OTA and  KBrO3, while 
both cell lines were similar sensitive to the other compounds. 
In the cellular assays and from phase contrast morphology 
only  KBrO3 and/or CsA showed a strong effect and only at 
the highest concentration applied, thus transcriptomic sig-
natures were far more sensitive than these assays.
An advantage of TempO-Seq (and other sequencing-
based techniques) is the possibility to use linear mRNA 
counts. While log2 control readouts are useful, especially for 
visualisation, it can also reduce data to sometimes biological 
meaningless information, especially where untreated values 
are close to zero. This phenomenon is well represented here 
in the comparison of the non-transformed and the log2 trans-
formed data of the HepaRG-specific and RPTEC/TERT1-
specific compound responses (Fig. 5b and c, graphs vs heat 
maps).
Several mechanistic aspects of compound-induced effects 
could be garnered from the TempO-Seq analysis. OTA, a 
nephrotoxic carcinogenic mycotoxin in rodents (IARC 1993; 
Zhang et al. 2016), was the most potent compound used 
and exhibited a high impact on the selected pathways, i.e., 
ATF4, Nrf2 and p53 (Figs. 3, 4). However, this impact was 
uniquely an OTA-induced pathway suppression as none of 
the nine panel pathway genes were increased with increasing 
OTA exposures, in fact the majority were decreased by OTA 
(Fig. 5a). Similar observations have been reported with OTA 
previously in the context of Nrf2 suppression (Cavin et al. 
2006; Boesch-Saadatmandi et al. 2008; Limonciel and Jen-
nings 2013). OTA-induced suppression of stress responses 
may contribute, or even underlie, its toxicity and carcino-
genicity.  KBrO3, a group 2B human genotoxic carcinogen, 
mediated by oxidant activity (DeAngelo et al. 1998; Limon-
ciel et al. 2012), resulted in a strong concentration-dependent 
activation of the Nrf2 and p53 pathways in both cell types, 
while ATF4 was to a lesser extent activated. ASNS expres-
sion was even attenuated by  KBrO3. Cyclosporine A (CsA) 
is a cyclophilin binding calcineurin inhibitor and potent 
immunosuppressant, but is also a competitive inhibitor of 
the bile salt export pump (ABCB11) (Starokozhko et al. 
2017). CsA at supra-therapeutic concentrations (15 µM) 
has been shown to injure mitochondria and cause endoplas-
mic reticulum (ER) disturbances (Wilmes et al. 2013). Here, 
CsA showed predominately a strong activation of the ATF4 
genes, which is in keeping with previous findings (Wilmes 
et al. 2013). The anti-epileptic compound sodium valproate 
(VALP) has been linked with liver steatosis and renal proxi-
mal tubular dysfunction, potentially via β-oxidation inhi-
bition and mitochondrial dysfunction (Chang and Abbott 
2006; Komulainen et al. 2015; Willebrords et al. 2015; Hei-
dari et al. 2017). Here, VALP resulted in an activation of 
the Nrf2 pathway in both cell types and induced the ATF4 
regulated gene ASNS in HepaRG cells. Acetaminophen 
(APAP), the widely used analgesic is well documented to 
cause liver injury in high doses due to formation of the 
metabolite N-acetyl-p-benzoquinoneimine (NAPQI) and 
subsequent NAPQI covalent thiol reactivity, glutathione 
depletion, resulting in proteotoxicity and ER stress (Bessems 
and Vermeulen 2001). Here, APAP had a prominent effect 
on ATF4 genes in both cell types. The major target organ of 
INZ is considered to be the liver, where INZ metabolites are 
thought to bind covalently to proteins (Hassan et al. 2015; 
Metushi et al. 2016; Iorga et al. 2017). However, ISZ had the 
lowest impact here, and we did not observe an impact on any 
of the pathways investigated.
Many of the cell type-specific genes were also altered in 
response to compound exposures; 18 of these were selected 
for deeper analysis, 9 for HepaRG and 9 for RPTEC/TERT1. 
The hepatic phase I metabolising gene, CYP3A4 was sig-
nificantly induced in HepaRG by APAP and VALP, the lat-
ter having a biphasic response. Both compounds have been 
previously shown to be CYP3A4 inducers (Feierman et al. 
2002; Cerveny et  al. 2007). CsA and  KBrO3 decreased 
CYP3A4 expression. CsA suppression of CYP3A4 has 
also been previously reported (Amundsen et al. 2012). AFP 
was strongly induced by the carcinogens OTA and  KBrO3 
in HepaRG cells and to a lesser extent in RPTEC/TERT1 
cells. AFP is a well-recognised marker of a hepatic foetal 
phenotype and is also discussed as a marker of hepatocel-
lular carcinoma (Terentiev and Moldogazieva 2013). EREG, 
also a cancer associated protein (Riese and Cullum 2014), 
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was induced by OTA,  KBrO3 and VALP only in HepaRG 
cells. A2M, ARG1, BAAT, HNFA4, ADH1A and HPR 
were also affected by compound exposure and were for the 
most part down regulated. These genes are predominately 
liver expressed and HNF4A, for example, has been shown 
to be important in the maintenance of hepatic differentia-
tion, where its overexpression can rescue dedifferentiation 
processes (Späth and Weiss 1997). Globally the described 
alterations of these nine genes could be interpreted as com-
pound-induced dedifferentiation of the hepatic phenotype.
SPP1 was induced by OTA,  KBrO3 and CsA in RPTEC/
TERT1 cells. The induction of SPP1, which is more pre-
dominately expressed in native kidney tissue, has been pre-
viously associated with renal and not hepatic injury in rats 
in vivo (Dadarkar et al. 2010). APP, which has role in neural 
growth and repair (Dawkins and Small 2014) was induced 
by all compounds, with the exception of CsA. SLC7A5, is 
involved in large neutral amino acid reabsorption, is strongly 
expressed in renal tubules and is also inducible by ATF4 
(Han et al. 2013). SLC7A5 was induced by APAP, CsA and 
VALP. ME1, which is mildly expressed in the kidney in vivo 
under basal conditions, but is also under the transcriptional 
regulation of Nrf2 (Wu et al. 2011) was heavily increased by 
 KBrO3, CsA and VALP in RPTEC/TERT1 cells. BBOX1, 
CLDN2, ATP1B1, MUC1 and AMIGO2 were for the most 
part decreased by the compound panel. Since these five 
markers are highly expressed in kidney cells, their decrease 
may reflect a compound-induced dedifferentiation of the 
proximal tubule phenotype. ISZ, however, induced BBOX1, 
CLDN2, ATP1B1 and MUC1, whereas VALP induced 
ATP1B1, indicating a somewhat more complicated inter-
pretation for certain compounds.
In summary, RPTEC/TERT1 and HepaRG have simi-
lar sensitivities to the chosen compounds and exhibit 
both common and cell type-specific responses.  KBrO3 as 
expected had a clear activation of the Nrf2 and p53 path-
ways. Whereas, CsA and APAP were strong inducers of the 
ATF4 pathway. AFP and EREG, were often upregulated 
upon exposure in HepaRG cells, while A2M, ARG1, BAAT, 
HNF4A, ADH1A and HPR were most often down regulated. 
In RPTEC/TERT1 cells, SPP1, APP, SLC7A5 and ME1 
were commonly induced, while BBOX-1, CLDN2, ATP1B1, 
MUC1 and AMIGO2 were often decreased. SLC7A5 and 
ME1 appear to be renal-specific pathway reporters of ATF4 
and Nrf2, respectively.
In conclusion, this study shows that TempO-Seq is a 
robust and sensitive method to quantify chemical-induced 
transcriptomic alterations and also highlights the usefulness 
of quantitative transcriptomics to identify mechanistic and 
tissues-specific effects of chemicals.
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